REVIEW PAPER
Venous thromboembolism and sarcoidosis: co-incidence or coexistence?
Submission date: 2015-07-24
Final revision date: 2015-10-12
Acceptance date: 2015-10-13
Publication date: 2016-01-15
Cent Eur J Immunol 2015;40(4):477-480
KEYWORDS
ABSTRACT
The association between venous thromboembolism (VTE) and sarcoidosis has been reported recently, nevertheless the true incidence of co-incident sarcoidosis and VTE is unknown. Sarcoidosis as a chronic disease of immune dysregulation might be associated with an increased risk of VTE. The mechanisms responsible for VTE development are not clear and may be influenced by several factors: activity of inflammation, clinical characteristics of sarcoidosis and comorbidities. Pulmonary embolism (PE) as a potentially fatal condition should be considered in all of the patients with sarcoidosis in whom worsening of the respiratory status is diagnosed. A high plasma D-dimers (DD) level may be suggestive of VTE, nevertheless elevated plasma DD should be interpreted with caution, in the context of the active inflammatory process. If sarcoidosis appears to be one of risk factors for VTE development, further investigations are needed to define the pro-thrombotic phenotype of this disease.
REFERENCES (38)
1.
Baughman RP, Teirstein AS, Judson MA, et al. (2001): Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164: 1885-1889.
2.
Hasday JD, Bachwich PR, Lynch JP, Sitrin RG (1988): Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoidosis. Exp Lung Res 14: 261-278.
3.
Moller DR (1999): Cells and cytokines involved in the pathogenesis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 16: 24-31.
4.
Crawshaw AP, Wotton CJ, Yeates DG, et al. (2011): Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study. Thorax 66: 447-448.
5.
Swigris JJ, Olson AL, Huie TJ, et al. (2011): Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest 140: 1261-1266.
6.
Wynne JW, Ryerson GG, Dalovisio J (1979): Myocardial sarcoidosis complicated by mural thrombosis. Thorax 34: 127-129.
7.
Akova YA, Kansu T, Duman S (1993): Pseudotumor cerebri secondary to dural sinus thrombosis in neurosarcoidosis. J Clin Neuroophthalmol 13: 188-189.
8.
Byrne JV, Lawton CA (1983): Meningeal sarcoidosis causing intracranial hypertension secondary to dural sinus thrombosis. Br J Radiol 56: 755-757.
9.
Selvi A, Diakou M, Giannopoulos S, et al. (2009): Cerebral venous thrombosis in a patient with sarcoidosis. Intern Med 48: 723-725.
10.
Marc K, Bourkadi JE, Benamor J, Iraqi G (2008): Thoracic venous thrombosis in the course of sarcoidosis. Rev Mal Respir 25: 105-106.
11.
McLaughlin AM, McNicholas WT (2003): Sarcoidosis presenting as upper extremity venous thrombosis. Thorax 58: 552.
12.
Rebeiz TJ, Mahfouz R, Taher A, et al. (2009): Unusual presentation of a sarcoid patient: multiple arterial and venous thrombosis with chest lymphadenopathy. J Thromb Thrombolysis 28: 245-247.
13.
Moreno-Merlo F, Wanless IR, Shimamatsu K, et al. (1997): The role of granulomatous phlebitis and thrombosis in the pathogenesis of cirrhosis and portal hypertension in sarcoidosis. Hepatology 26: 554-560.
14.
Reitsma PH, Rosendaal FR (2004): Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost 2: 619-622.
15.
van Aken BE, den HM, Bos GM, et al. (2000): Recurrent venous thrombosis and markers of inflammation. Thromb Haemost 83: 536-539.
16.
Mana J, Salazar A, Manresa F (1994): Clinical factors predicting persistence of activity in sarcoidosis: a multivariate analysis of 193 cases. Respiration 61: 219-225.
17.
Muller-Quernheim J (1998): Serum markers for the staging of disease activity of sarcoidosis and other interstitial lung diseases of unknown etiology. Sarcoidosis Vasc Diffuse Lung Dis 15: 22-37.
18.
Neville E, Walker AN, James DG (1983): Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 52: 525-533.
19.
Takizawa H, Satoh M, Okazaki H, et al. (1997): Increased IL-6 and IL-8 in bronchoalveolar lavage fluids (BALF) from patients with sarcoidosis: correlation with the clinical parameters. Clin Exp Immunol 107: 175-181.
20.
Hunninghake GW, Crystal RG (1981): Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes. J Clin Invest 67: 86-92.
21.
Miyara M, Amoura Z, Parizot C, et al. (2006): The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 203: 359-370.
23.
Cermak J, Key NS, Bach RR, et al. (1993): C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82: 513-520.
24.
Chapman HA, Allen CL, Stone OL (1986): Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis 133: 437-443.
25.
Shorr AF, Thomas SJ, Alkins SA, et al. (2002): D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest 121: 1262-1268.
26.
Baydur A, Alavy B, Nawathe A, et al. (2011): Fatigue and plasma cytokine concentrations at rest and during exercise in patients with sarcoidosis. Clin Respir J 5: 156-164.
27.
Kawaguchi H, Ina Y, Sato S, et al. (1995): Serum levels of soluble receptors for tumor necrosis factor in sarcoidosis. Nihon Kyobu Shikkan Gakkai Zasshi 33: 850-855.
28.
De AV, Scurati S, Raschi E, et al. (2009): Pro-inflammatory genotype as a risk factor for aPL-associated thrombosis: Report of a family with multiple anti-phospholipid positive members. J Autoimmun 32: 60-63.
29.
Bingisser R, Speich R, Zollinger A, et al. (2000): Interleukin-10 secretion by alveolar macrophages and monocytes in sarcoidosis. Respiration 67: 280-286.
30.
Alvarez RA, Barbash IJ, Rose JJ (2014): Bosentan for sarcoidosis-associated pulmonary hypertension, age-adjusted D-dimer levels in pulmonary embolism, and mean arterial blood pressure targets in septic shock. Am J Respir Crit Care Med 190: 948-949.
31.
Costabel U, Hunninghake GW (1999): ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J 14: 735-737.
32.
Rosen Y, Moon S, Huang CT, et al. (1977): Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med 101: 170-174.
33.
Wilson WA, Gharavi AE, Koike T, et al. (1999): International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42: 1309-1311.
34.
Ina Y, Takada K, Yamamoto M, et al. (1994): Antiphospholipid antibodies. A prognostic factor in sarcoidosis? Chest 105: 1179-1183.
36.
Lensen RP, Bertina RM, de RH, Vandenbroucke JP, Rosendaal FR (2000): Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost 83: 817-821.
37.
Hedfors E (1977): Anticoagulant treatment in sarcoidosis. Acta Med Scand 202: 237-240.
38.
Downing LJ, Strieter RM, Kadell AM, et al. (1998): Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis. J Vasc Surg 28: 848-854.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
